Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2012
10/23/2012CA2555279C Azepinoindole derivatives as pharmaceutical agents
10/23/2012CA2547243C N-aryl piperidine substituted biphenylcarboxamides
10/23/2012CA2545584C Methods and compositions for the treatment of metabolic disorders
10/23/2012CA2537962C Crystalline form of bis [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6 -enoicacid] calcium salt
10/23/2012CA2534128C Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation
10/23/2012CA2528284C Use of pyrazolopyridines for the treatment of cognitive deficits
10/23/2012CA2527703C New use of staurosporine derivatives
10/23/2012CA2523178C Materials and methods to potentiate cancer treatment
10/23/2012CA2522379C The severe acute respiratory syndrome coronavirus
10/23/2012CA2518738C Method and composition for preventing or reducing diarrhea
10/23/2012CA2515892C Lipophilic drug delivery vehicle and methods of use thereof
10/23/2012CA2513567C Cop 1 for treatment of inflammatory bowel diseases
10/23/2012CA2508303C Drug delivery system using subconjunctival depot
10/23/2012CA2498022C Combination of mglur antagonists for the treatment of addictive disorders
10/23/2012CA2488635C Antagonists of melanin concentrating hormone receptor
10/23/2012CA2441410C Compounds and method of treatment having agonist-like activity selective at alpha 2b or 2b/2c adrenergic receptors
10/23/2012CA2429009C A method for restoring a fat-pad
10/23/2012CA2384978C Udp-n-acetylglucosamine: galactose-.beta.1,3-n-acetylgalactosamine-.alpha.-r/(glcnac to galnac) .beta.1,6-n-acetylglucosaminyltransferase, c2gnt3
10/23/2012CA2382805C Gel compositions
10/23/2012CA2219119C Nucleic acid ligand complexes
10/18/2012WO2012142622A1 Agents for improved delivery of nucleic acids to eukaryotic cells
10/18/2012WO2012142615A2 Auranofin and auranofin analogs useful to treat proliferative disease and disorders
10/18/2012WO2012142581A1 Treatment of disease with poly-n-acety glucosamine nanofibers
10/18/2012WO2012142575A2 Monomeric trioxane amide sulfur compounds
10/18/2012WO2012142523A2 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
10/18/2012WO2012142520A2 Unit dose form for oral administration
10/18/2012WO2012142513A1 Substituted benzene compounds
10/18/2012WO2012142504A1 Aryl-or heteroaryl-substituted benzene compounds
10/18/2012WO2012142476A2 Methods and compositions for the treatment of marfan syndrome and associated disorders
10/18/2012WO2012142474A2 N-acetyl beta alanine methods of use
10/18/2012WO2012142459A1 Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
10/18/2012WO2012142457A2 Macrolactam compounds and methods for the treatment of malaria
10/18/2012WO2012142388A2 Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders
10/18/2012WO2012142377A1 Bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
10/18/2012WO2012142372A2 Compositions and methods for the treatment of nasal conditions
10/18/2012WO2012142367A2 Compositions and methods for treatment of pulmonary diseases and conditions
10/18/2012WO2012142325A1 Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset
10/18/2012WO2012142308A1 Prodrugs of inhibitors of plasma kallikrein
10/18/2012WO2012142288A1 Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
10/18/2012WO2012142281A1 Solid pharmaceutical composition
10/18/2012WO2012142268A1 Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
10/18/2012WO2012142256A2 Modulators of mitochondrial protein import
10/18/2012WO2012142255A1 Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators
10/18/2012WO2012142237A1 Fused imidazole derivatives useful as ido inhibitors
10/18/2012WO2012142208A1 Bifunctional akr1c3 inhibitors/androgen receptor modulators and methods of use thereof
10/18/2012WO2012142160A1 Methods for inhibiting allograft rejection
10/18/2012WO2012142145A1 Methods of treating skin conditions exhibiting telangiectasia
10/18/2012WO2012142141A1 Synthesis and use of glycoside pro-drug analogs
10/18/2012WO2012142117A1 Solid state forms of cabazitaxel and processes for preparation thereof
10/18/2012WO2012142085A1 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
10/18/2012WO2012142083A2 C1q/tnf-related protein 12 and compositions and methods of using same
10/18/2012WO2012142080A1 Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
10/18/2012WO2012142067A2 Formulations, salts, and solid forms of substituted cyclohexylmethanamines, processes for preparation, and uses thereof
10/18/2012WO2012142039A1 Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
10/18/2012WO2012142029A2 Serms for the treatment of estrogen receptor-mediated disorders
10/18/2012WO2012141990A1 Parp inhibitors for the treatment of cipn
10/18/2012WO2012141971A2 Methods and compositions for rejuvenation and expansion of stem cells
10/18/2012WO2012141815A1 Use of n-(4-methoxyphenyl)-1-phenyl-1h-pyrazol-3-amine and related compounds
10/18/2012WO2012141796A2 Prostate cancer therapy with hsp90 inhibitory compounds
10/18/2012WO2012141773A1 Methods and compositions for reducing shiga toxin induced toxicity in mammals
10/18/2012WO2012141704A1 Compounds for the treatment of hepatitis c
10/18/2012WO2012141615A2 Medicament
10/18/2012WO2012141604A1 Asymmetrically substituted anthrapyridazone derivatives as cytostatics
10/18/2012WO2012141590A1 Combination of epa, dpa and/or dha with a chemotherapeutic agent
10/18/2012WO2012141575A1 Combination of epa, dpa and/or dha with a chemotherapeutic agent
10/18/2012WO2012141553A2 Stabilizing composition for tetrahydrobiopterin, and method for analyzing tetrahydrobiopterin using same
10/18/2012WO2012141536A2 Composition for regenerating connective tissue, and method for regenerating connective tissue
10/18/2012WO2012141502A2 Controlled release type tablet containing aceclofenac
10/18/2012WO2012141487A2 Cycloalkenyl aryl derivatives for cetp inhibitor
10/18/2012WO2012141385A1 Antihypertensive pharmaceutical composition
10/18/2012WO2012141338A1 6,7 - dihydroimidazo [2, 1 - b] [1, 3] oxazine bactericides
10/18/2012WO2012141334A1 Aqueous ophthalmic composition
10/18/2012WO2012141316A1 Nutritional composition
10/18/2012WO2012141256A1 Method for activating good intestinal bacterium, and composition for activating good intestinal bacterium
10/18/2012WO2012141228A1 Novel pyrazole derivative
10/18/2012WO2012141160A1 Pitavastatin-containing preparation and method for producing same
10/18/2012WO2012141018A1 Composition, glucose metabolism-improving agent, and method for improving glucose metabolism
10/18/2012WO2012140894A1 Pharmaceutical composition
10/18/2012WO2012140642A1 Heterocyclic compounds and uses thereof in the treatment of sexual disorders
10/18/2012WO2012140632A1 Febuxostat solid dispersion
10/18/2012WO2012140612A1 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
10/18/2012WO2012140604A1 Stable formulations of pramipexole hydrochloride
10/18/2012WO2012140597A1 Glycoside derivatives and their uses for the treatment of diabetes
10/18/2012WO2012140596A1 Glycoside derivatives and uses thereof
10/18/2012WO2012140580A1 Polysaccharides comprising two antithrombin iii-binding sites, preparation thereof and use thereof as antithrombotic medicaments
10/18/2012WO2012140577A1 Modified release pharmaceutical compositions of desvenlafaxine
10/18/2012WO2012140574A1 Substituted catechols as inhibitors of il-4 and il-5 for the treatment bronchial asthma
10/18/2012WO2012140516A2 Non human animal model for ulcerative colitis and its main complications
10/18/2012WO2012140504A1 Therapeutic compounds
10/18/2012WO2012140436A1 Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
10/18/2012WO2012140419A1 Chromenone compounds as pi 3 -kinase inhibitors for the treatment of cancer
10/18/2012WO2012140365A1 Use of calixarenes associated with an antibiotic in the treatment of bacterial infections
10/18/2012WO2012140364A1 Use of calixarenes in the treatment of bacterial infections
10/18/2012WO2012140351A2 Caffeine and triacanthine composition for treating excess fat
10/18/2012WO2012140300A1 Compounds and compositions for treating multiple myeloma
10/18/2012WO2012140298A1 Use of yessotoxins and the derivatives thereof for the treatment and/or prevention of metabolic diseases
10/18/2012WO2012140272A1 Treatment of microbial infections
10/18/2012WO2012140243A1 Inhibitors of viral replication, their process of preparation and their therapeutical uses
10/18/2012WO2012140234A1 Modulation of mirna in diseases with aberrant angiogenesis
10/18/2012WO2012140208A1 Screening methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases
1 ... 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 ... 7860